About Durata Therapeutics (NASDAQ:DRTX)
Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia. As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Durata Therapeutics (NASDAQ:DRTX) Frequently Asked Questions
What is Durata Therapeutics' stock symbol?
Durata Therapeutics trades on the NASDAQ under the ticker symbol "DRTX."
Who are some of Durata Therapeutics' key competitors?
Some companies that are related to Durata Therapeutics include Iqvia (IQV), Incyte (INCY), Nektar Therapeutics (NKTR), Alnylam Pharmaceuticals (ALNY), Alkermes (ALKS), Qiagen (QGEN), Seattle Genetics (SGEN), SAGE Therapeutics (SAGE), Ionis Pharmaceuticals (IONS), Covance (CVD), Icon (ICLR), Galapagos (GLPG), PRA Health Sciences (PRAH), United Therapeutics (UTHR), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), EXACT Sciences (EXAS) and FibroGen (FGEN).
How do I buy Durata Therapeutics stock?
Shares of Durata Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Durata Therapeutics?
Durata Therapeutics' mailing address is 200 S Wacker Dr Ste 2550, CHICAGO, IL 60606-5811, United States. The biotechnology company can be reached via phone at +1-312-2197000.
MarketBeat Community Rating for Durata Therapeutics (DRTX)MarketBeat's community ratings are surveys of what our community members think about Durata Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Durata Therapeutics (NASDAQ:DRTX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Durata Therapeutics (NASDAQ:DRTX) Earnings History and Estimates Chart
Durata Therapeutics (NASDAQ DRTX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Durata Therapeutics (NASDAQ:DRTX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Durata Therapeutics (NASDAQ:DRTX)
No dividend announcements for this company have been tracked by MarketBeat.com
Durata Therapeutics (NASDAQ DRTX) Insider Trading and Institutional Ownership History
Durata Therapeutics (NASDAQ DRTX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|8/12/2014||John Patrick Shannon Jr||Insider||Buy||3,000||$13.72||$41,160.00|| |
|6/12/2014||Paul R Edick||CEO||Buy||3,000||$15.23||$45,690.00|| |
|5/12/2014||Schutter Richard De||Director||Buy||15,000||$15.57||$233,550.00||15,000|| |
|3/21/2014||Aisling Capital Iii Lp||major shareholder||Sell||100,649||$15.74||$1,584,215.26|| |
|12/3/2013||Lisa Giles||Director||Buy||1,000||$10.95||$10,950.00||1,000|| |
|5/20/2013||Paul R Edick||CEO||Buy||3,000||$7.09||$21,270.00|| |
|8/14/2012||Paul R Edick||CEO||Buy||5,000||$8.65||$43,250.00|| |
Durata Therapeutics (NASDAQ DRTX) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Durata Therapeutics (NASDAQ:DRTX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Durata Therapeutics (NASDAQ:DRTX) Income Statement, Balance Sheet and Cash Flow Statement
Durata Therapeutics (NASDAQ DRTX) Stock Chart for Friday, February, 23, 2018